要点速览由于成本大幅上升,福泰制药未达到第一季度的利润和营收预期。这家生物技术公司还因在俄罗斯的知识产权侵权问题,导致美国以外地区的销售额下降。鉴于对其囊性纤维化治疗药物的需求增加,福泰制药提高了 2025 年业绩指引的下限。福泰制药(VRTX)的股价在周二暴跌了 12%,此前一天这家生物技术公司公布了因成本上升而不及预期的业绩。福泰制药公布的第一季度调整后每股收益为 4.06 美元,营收同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.